Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

CHEN Kai-yu, LI Xin-ping, CHEN Sheng-xin. Progress on positron emission tomography drugs[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 175-177. doi: 10.3969/j.issn.1006-0111.2012.03.006
Citation: CHEN Kai-yu, LI Xin-ping, CHEN Sheng-xin. Progress on positron emission tomography drugs[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 175-177. doi: 10.3969/j.issn.1006-0111.2012.03.006

Progress on positron emission tomography drugs

doi: 10.3969/j.issn.1006-0111.2012.03.006
  • Received Date: 2012-05-11
  • Rev Recd Date: 2012-05-15
  • Because of the urgent needs of the medical advances and clinical diagnosis practice, positron emission tomography drugs were increasingly widely researched and used. The characteristics and the course of the development of positron emission tomography drugs were reviewed at home and abroad. Based on the current status of positron emission tomography drugs in China, the ideas of promoting the research, production and clinical application of positron emission tomography drugs were also discussed in this paper.
  • [1] U.S. Food and Drug Administration. Positron Emission Tomography (PET): Questions and Answers about CGMP Regulations for PET Drugs[EB/OL].(2009-12-9)[2012-4-30]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm193476.htm.
    [2] 金征宇. 医学影像学[M]. 第2版.北京:人民卫生出版社,2010:20.
    [3] 张锦明, 田嘉禾. 国内正电子放射性药物发展现状简介[J]. 同位素,2006,19(4):240.
    [4] 国家食品药品监督管理局,卫生部. 医疗机构制备正电子类放射性药品管理规定[EB/OL]. (2006-1-5)[2012-4-30]. http://www.sda.gov.cn/WS01/CL0058/9355.html.
    [5] Ido T, Wan CN, Fowler JS, et al. Fluorination with F2:convenient synthesis of 2-deoxy-2-fluoro-D-glucose[J] J Org Chem,1977,42: 2341.
    [6] Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution[J]. J Nucl Med,1986,27:235.
    [7] Fuchtner F, Steinbach J, Mading P. Basic previous term hydrolysis next term 2-[18F]fluoro-1,3,4,6-tetra-O-acetyl-image-glucose in the preparation of 2-[18F]fluoro-2-deoxy-Image-glucose[J]. Appl Radiat Isot,1996,47:61.
    [8] Shankar V, Lilja S, Brigitte V. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: What is new?[J]. Semin Nucl Med,2011, 41: 246.
    [9] International Atomic Energy Agency. Nuclear Technology Review 2010[R/OL].(2010-8-10)[2012-4-30].http://www.iaea.org/About/Policy/GC/GC54/GC54InfDocuments/English/gc54inf-3_en.pdf.
    [10] U.S. Food and Drug Administration. Drug information[DB/OL]. [2012-4-30]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
    [11] 中华医学会核医学分会. 2010年全国核医学现状普查[J].中华核医学杂志,2010,30(6):428.
    [12] 梁银杏,叶 桦. 关于我国正电子放射性药品新药注册管理的建议[J]. 中国新药与临床杂志,2012,31(2):68.
    [13] 张锦明. 正电子放射性药物进展[J]. 中华核医学杂志,2003,23(5):315.
    [14] 周 克,杨 勤,向 燕. 正电子放射性药物的现状与进展[J]. 西南军医,2005,7(2):47.
    [15] 卫生部. 中华人民共和国卫生部批准配置PET/CT医疗机构名单[J]. 中华核医学杂志,2010,30(6):418.
    [16] 卫生部. 2011~2015年全国正电子发射型断层扫描仪配置规划 [EB/OL].(2011-11-2)[2012-4-30]http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohghcws/s3585/201111/53257.htm.
    [17] 国家食品药品监督管理局,卫生部. 正电子类放射性药品质量控制指导原则[EB/OL].(2006-1-5)[2012-4-30]. http://www.sda.gov.cn/WS01/CL0058/9355_6.html.
    [18] USP 32-NF 27[S]. 2008: 2406.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(12796) PDF downloads(2014) Cited by()

Related
Proportional views

Progress on positron emission tomography drugs

doi: 10.3969/j.issn.1006-0111.2012.03.006

Abstract: Because of the urgent needs of the medical advances and clinical diagnosis practice, positron emission tomography drugs were increasingly widely researched and used. The characteristics and the course of the development of positron emission tomography drugs were reviewed at home and abroad. Based on the current status of positron emission tomography drugs in China, the ideas of promoting the research, production and clinical application of positron emission tomography drugs were also discussed in this paper.

CHEN Kai-yu, LI Xin-ping, CHEN Sheng-xin. Progress on positron emission tomography drugs[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 175-177. doi: 10.3969/j.issn.1006-0111.2012.03.006
Citation: CHEN Kai-yu, LI Xin-ping, CHEN Sheng-xin. Progress on positron emission tomography drugs[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 175-177. doi: 10.3969/j.issn.1006-0111.2012.03.006
Reference (18)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return